SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-125386
Filing Date
2024-11-12
Accepted
2024-11-12 16:10:09
Documents
13
Period of Report
2024-11-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K oric-20241112.htm   iXBRL 8-K 55232
2 EX-99.1 oric-ex99_1.htm EX-99.1 147920
3 GRAPHIC img48504584_0.jpg GRAPHIC 54202
  Complete submission text file 0000950170-24-125386.txt   416515

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT oric-20241112.xsd EX-101.SCH 32755
15 EXTRACTED XBRL INSTANCE DOCUMENT oric-20241112_htm.xml XML 4899
Mailing Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 240 E. GRAND AVE. 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 388-5600
Oric Pharmaceuticals, Inc. (Filer) CIK: 0001796280 (see all company filings)

IRS No.: 471787157 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39269 | Film No.: 241448162
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)